Concepedia

Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy

Daniel Q. Huang, Mark Muthiah, Lei Zhou, Nur Halisah Binte Jumat, Wan Xin Tan, Guan Huei Lee, Seng Gee Lim, Alfred Wei Chieh Kow, Glenn Kunnath Bonney, Shridhar Ganpathi Iyer,

Cellular and Molecular Gastroenterology and Hepatology · 2020 · 16 citations · 24 references

DOIFull text

Open access

Abstract

A clinically relevant cirrhotic PDX model preserves tumor angiogenesis and allows prediction of response to multikinase inhibitors for personalized therapy.

References

24

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 12.8K citations · Full text

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 6.8K citations · Full text

Sorafenib in Advanced Hepatocellular Carcinoma

재연 정 · 2008 · 5.6K citations

, , +5

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

, , +11

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

, , +12